ATE478707T1 - Kim-1-antikörper zur behandlung von th2- vermittelten erkrankungen - Google Patents
Kim-1-antikörper zur behandlung von th2- vermittelten erkrankungenInfo
- Publication number
- ATE478707T1 ATE478707T1 AT06736714T AT06736714T ATE478707T1 AT E478707 T1 ATE478707 T1 AT E478707T1 AT 06736714 T AT06736714 T AT 06736714T AT 06736714 T AT06736714 T AT 06736714T AT E478707 T1 ATE478707 T1 AT E478707T1
- Authority
- AT
- Austria
- Prior art keywords
- kim
- antibodies
- treatment
- mediated diseases
- mediated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65778905P | 2005-03-02 | 2005-03-02 | |
PCT/US2006/007441 WO2006094134A2 (en) | 2005-03-02 | 2006-03-02 | Kim-1 antibodies for treatment of th2-mediated conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE478707T1 true ATE478707T1 (de) | 2010-09-15 |
Family
ID=36648475
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06736714T ATE478707T1 (de) | 2005-03-02 | 2006-03-02 | Kim-1-antikörper zur behandlung von th2- vermittelten erkrankungen |
Country Status (15)
Country | Link |
---|---|
US (2) | US8206705B2 (de) |
EP (2) | EP2251037B1 (de) |
JP (2) | JP2008531719A (de) |
KR (1) | KR101213894B1 (de) |
CN (2) | CN101166542A (de) |
AT (1) | ATE478707T1 (de) |
AU (2) | AU2006218489B2 (de) |
BR (1) | BRPI0608254A2 (de) |
CA (1) | CA2599967C (de) |
DE (1) | DE602006016413D1 (de) |
HK (1) | HK1118007A1 (de) |
IL (1) | IL185653A (de) |
NZ (1) | NZ562045A (de) |
WO (1) | WO2006094134A2 (de) |
ZA (1) | ZA200708372B (de) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008064031A2 (en) * | 2006-11-13 | 2008-05-29 | Government Of The United States, As Represented Bythe Secretary Of The Department Of Health And Human Services | Potent activation of antigen presenting cells by the hepatitis a virus cellular receptor 1 and its role in the regulation of immune responses |
CA2833785C (en) | 2011-04-21 | 2022-06-07 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for the treatment of neuromyelitis optica |
CN108472365A (zh) | 2015-10-30 | 2018-08-31 | 艾丽塔生物治疗剂公司 | 用于肿瘤转导的组合物和方法 |
EP3368559A4 (de) | 2015-10-30 | 2020-01-15 | Aleta Biotherapeutics Inc. | Zusammensetzungen und verfahren zur behandlung von krebs |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
EP0307434B2 (de) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Geänderte antikörper |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
DK0678122T3 (da) | 1993-01-12 | 2000-03-06 | Biogen Inc | Rekombinante anti-VLA4 antistofmolekyler |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US5622861A (en) | 1994-08-05 | 1997-04-22 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA encoding hepatitis A virus receptor |
US6066322A (en) * | 1995-03-03 | 2000-05-23 | Millennium Pharmaceuticals, Inc. | Methods for the treatment of immune disorders |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
DE19541844C1 (de) | 1995-11-09 | 1997-07-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung |
US6165733A (en) | 1996-05-23 | 2000-12-26 | Chiron Corporation | γ II adaptin |
PT907735E (pt) * | 1996-05-24 | 2006-06-30 | Biogen Idec Inc | Moduladores da regeneracao de tecidos |
EP0948597A4 (de) | 1996-11-01 | 2002-07-10 | Human Genome Sciences Inc | Menschliches, Schleimhaut-spezifisches Addressin-Zelladhäsionsmolekül (MAdCAM-1) und dessen Spleissvarianten |
EP1972194A1 (de) | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Transgene Säugetiere mit menschlichen IG-Orten mit mehreren VH- und VK-Regionen und darin erzeugten Antikörpern |
JP4094066B2 (ja) | 1996-12-06 | 2008-06-04 | バーテックス ファーマシューティカルズ インコーポレイテッド | インターロイキン−1β変換酵素のインヒビター |
PT1818343E (pt) | 1998-01-23 | 2012-07-12 | Hoffmann La Roche | Anticorpos contra a il-12 humana |
CA2323443A1 (en) | 1998-03-11 | 1999-09-16 | Mitsubishi Pharma Corporation | Ige antibody production inhibitors and autoimmune diseases inhibitors |
US6228642B1 (en) | 1998-10-05 | 2001-05-08 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression |
US8288322B2 (en) | 2000-04-17 | 2012-10-16 | Dyax Corp. | Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries |
US7179901B2 (en) * | 2000-06-16 | 2007-02-20 | Biogen Idec Ma Inc. | Renal regulatory elements and methods of use thereof |
WO2002098920A1 (en) * | 2001-06-01 | 2002-12-12 | Biogen, Inc. | Molecules and methods for inhibiting shedding of kim-1 |
US7838220B2 (en) * | 2001-06-29 | 2010-11-23 | The Board Of Trustees Of The Leland Stanford Junior University | T cell regulatory genes associated with immune disease |
JP4572276B2 (ja) * | 2001-06-29 | 2010-11-04 | ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニヴァーシティ | T細胞調節遺伝子およびその使用方法 |
EP1434881A4 (de) | 2001-09-17 | 2005-10-26 | Protein Design Labs Inc | Verfahren zur diagnose von krebszusammensetzungen und verfahren zum screening auf krebsmodulatoren |
WO2003042661A2 (en) | 2001-11-13 | 2003-05-22 | Protein Design Labs, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
US7687454B2 (en) * | 2001-12-03 | 2010-03-30 | The University Of British Columbia | Effectors of innate immunity determination |
AU2003303082B2 (en) * | 2002-01-30 | 2009-07-02 | Dana-Farber Cancer Institute, Inc. | Compositions and methods related to TIM-3, a Th1-specific cell surface molecule |
AU2003228336B2 (en) * | 2002-03-19 | 2009-07-30 | Curagen Corporation | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
GB0215509D0 (en) | 2002-07-04 | 2002-08-14 | Novartis Ag | Marker genes |
CN1835769B (zh) * | 2002-12-30 | 2011-06-29 | 比奥根艾迪克Ma公司 | Kim-1拮抗剂及其在免疫***调节中的应用 |
WO2004084823A2 (en) | 2003-03-19 | 2004-10-07 | Abgenix, Inc. | Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof |
WO2005001092A2 (en) | 2003-05-20 | 2005-01-06 | Wyeth | Compositions and methods for diagnosing and treating cancers |
TW200539890A (en) * | 2004-03-12 | 2005-12-16 | Brigham & Womens Hospital | Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function |
KR20070037570A (ko) * | 2004-03-24 | 2007-04-05 | 텔로스 파마슈티칼스 인코포레이티드 | 백신에 대한 면역반응을 향상시키는 보강제로서의 조성물및 이의 사용 방법 |
US8025557B2 (en) | 2009-02-27 | 2011-09-27 | Illinois Tool Works Inc. | Sanding clay |
-
2006
- 2006-03-02 CN CNA2006800139893A patent/CN101166542A/zh active Pending
- 2006-03-02 CN CN201410043208.1A patent/CN103751780A/zh active Pending
- 2006-03-02 AU AU2006218489A patent/AU2006218489B2/en not_active Ceased
- 2006-03-02 US US11/817,638 patent/US8206705B2/en not_active Expired - Fee Related
- 2006-03-02 AT AT06736714T patent/ATE478707T1/de not_active IP Right Cessation
- 2006-03-02 NZ NZ562045A patent/NZ562045A/en not_active IP Right Cessation
- 2006-03-02 DE DE602006016413T patent/DE602006016413D1/de active Active
- 2006-03-02 EP EP10173620.5A patent/EP2251037B1/de not_active Not-in-force
- 2006-03-02 CA CA2599967A patent/CA2599967C/en not_active Expired - Fee Related
- 2006-03-02 BR BRPI0608254-8A patent/BRPI0608254A2/pt not_active IP Right Cessation
- 2006-03-02 WO PCT/US2006/007441 patent/WO2006094134A2/en active Application Filing
- 2006-03-02 KR KR1020077022608A patent/KR101213894B1/ko not_active IP Right Cessation
- 2006-03-02 EP EP06736714A patent/EP1865985B1/de active Active
- 2006-03-02 JP JP2007558223A patent/JP2008531719A/ja not_active Withdrawn
-
2007
- 2007-09-02 IL IL185653A patent/IL185653A/en not_active IP Right Cessation
- 2007-10-01 ZA ZA200708372A patent/ZA200708372B/xx unknown
-
2008
- 2008-06-19 HK HK08106807.2A patent/HK1118007A1/xx not_active IP Right Cessation
-
2011
- 2011-05-24 AU AU2011202405A patent/AU2011202405B2/en not_active Ceased
-
2012
- 2012-03-28 JP JP2012073852A patent/JP2012131825A/ja active Pending
- 2012-04-04 US US13/439,413 patent/US20130089539A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2008531719A (ja) | 2008-08-14 |
AU2011202405B2 (en) | 2013-03-28 |
CA2599967A1 (en) | 2006-09-08 |
EP1865985B1 (de) | 2010-08-25 |
AU2011202405A1 (en) | 2011-06-09 |
WO2006094134A3 (en) | 2006-10-19 |
US20100150905A1 (en) | 2010-06-17 |
WO2006094134A2 (en) | 2006-09-08 |
EP1865985A2 (de) | 2007-12-19 |
HK1118007A1 (en) | 2009-01-30 |
KR101213894B1 (ko) | 2012-12-20 |
JP2012131825A (ja) | 2012-07-12 |
IL185653A (en) | 2013-04-30 |
AU2006218489B2 (en) | 2011-02-24 |
CA2599967C (en) | 2014-10-21 |
ZA200708372B (en) | 2008-12-31 |
AU2006218489A1 (en) | 2006-09-08 |
EP2251037B1 (de) | 2015-01-14 |
CN101166542A (zh) | 2008-04-23 |
KR20070110411A (ko) | 2007-11-16 |
DE602006016413D1 (de) | 2010-10-07 |
US8206705B2 (en) | 2012-06-26 |
US20130089539A1 (en) | 2013-04-11 |
IL185653A0 (en) | 2008-01-06 |
EP2251037A1 (de) | 2010-11-17 |
NZ562045A (en) | 2010-12-24 |
CN103751780A (zh) | 2014-04-30 |
BRPI0608254A2 (pt) | 2009-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602005023172D1 (de) | Hydantoinderivate zur behandlung von entzündlichen erkrankungen | |
ATE369333T1 (de) | Sulfonamidderivate zur behandlung von krankheiten | |
ATE375977T1 (de) | Sulfonamidderivate zur behandlung von krankheiten | |
DE60303238D1 (de) | Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten | |
ATE550338T1 (de) | Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
ATE447551T1 (de) | Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen | |
DE602005005810D1 (de) | Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen | |
ATE476414T1 (de) | Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen | |
ATE434620T1 (de) | Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen | |
DE602005007717D1 (de) | Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen | |
ATE512663T1 (de) | Kombination zur behandlung von erkrankungen mit zellproliferation | |
ATE527241T1 (de) | Pyridiazinonderivate zur behandlung von tumoren | |
DE602005026984D1 (de) | Chinolin-derivate zur behandlung von latenter tuberkulose | |
ATE542823T1 (de) | 4,5-dihydro-ä1,2,4ütriazoloä4,3-füpteridine als plk1-proteinkinasehemmer zur behandlung proliferativer erkrankungen | |
ATE482709T1 (de) | Neue arzneimittelkombinationen zur behandlung von atemwegserkrankungen | |
DE602005023452D1 (de) | Mit calcitriol und clobetasolpropionat zur behandlung von schuppenflechte | |
DE502006008804D1 (de) | Neue, langwirksame betamimetika zur behandlung von atemwegserkrankungen | |
ATE443704T1 (de) | Pyridopyrimidinone zur behandlung von krebserkrankungen | |
DE602006003094D1 (de) | 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit | |
DE602005016141D1 (de) | S-mirtazapin zur behandlung von hitzewallungen | |
DE602005013650D1 (de) | Proteinhydrolysat zur behandlung von müdigkeit | |
ATE478707T1 (de) | Kim-1-antikörper zur behandlung von th2- vermittelten erkrankungen | |
DE602005013287D1 (de) | Zusammensetzung zur behandlung von leder | |
DE602005015434D1 (de) | Mittel zur behandlung von psychoneurotischen krankheiten | |
ATE482707T1 (de) | 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |